Clinical trials: Resectable Head and Neck Squamous Cell Carcinoma
Mouth Neoplasms
Oral Cancer Adjuvant Therapy (OCAT) Trial
To demonstrate whether addition of Concurrent chemotherapy to post-operative adjuvant radiotherapy OR shortening of duration of post-operative radiotherapy, by administering 6 fractions / week instead of 5 fractions / week…
- Trial name
- NCT00193843
- Testing
- Post-operative chemoradiotherapy / accelerated radiotherapy
- Where
- India
- Volunteers
- 900 people
- Sponsor
- Tata Memorial Hospital
Lung Cancer, Non-small Cell Lung Cancer
Effects of Infusion Timing on Treatment Response in Solid Tumors
This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer
- Trial name
- TIMED (NCT07630168)
- Testing
- PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Stage III Oral Cavity Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma
TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or…
- Trial name
- NCT01542931
- Testing
- TPF induction chemotherapy
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Esophageal Squamous Cell Carcinoma
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Esophageal cancer is one of common malignant tumors in China and esophageal squamous cell carcinoma (ESCC) is the dominant pathological type, accounting for more than 95% of all cases.
- Trial name
- NCT02272699
- Testing
- Nimotuzumab, Paclitaxel, Cisplatin
- Where
- China
- Sponsor
- Peking University
Locally Advanced Head and Neck Squamous Cell Carcinoma
Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Over 60% of head and neck squamous cell carcinoma (HNSCC) patients are diagnosed at a locally advanced stage. While standard treatments involve surgery and chemoradiotherapy, prognosis remains poor, with 50-60% experiencing local…
- Trial name
- NCT07371234
- Testing
- Neoadjuvant and Adjuvant Immunotherapy, Low-dose radiotherapy, Surgery
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Rui You
Head and Neck Squamous Cell Carcinoma
Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC
Head and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge, as over 60% of patients are diagnosed at a locally advanced stage with a high risk of recurrence.
- Trial name
- NCT07572864
- Testing
- Engineered Mitochondrial Vaccine (IMP3-Mito), Immune checkpoint inhibitor (ICI)
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer.
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT01898494
- Testing
- Transoral surgery, intensity-modulated radiation therapy, cisplatin
- Where
- 58 sites in United States
- Volunteers
- 519 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Esophageal Squamous Cell Carcinoma
Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer
This study aims to investigate the safety and efficacy of sintilimab combined with platinum-based chemotherapy in neoadjuvant treatment of potentially resectable esophageal cancer.
- Trial name
- NCT03946969
- Testing
- Sintilimab, Liposomal Paclitaxel + Cisplatin + S-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Adjuvant Radiotherapy
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
This study is a multicenter, prospective, randomized phase II trial aimed at exploring the value of adjuvant radiotherapy in patients at high risk of recurrence after neoadjuvant chemoradiotherapy for esophageal cancer.
- Trial name
- NCT06272214
- Testing
- Adjuvant radiotherapy, Observation
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Zhejiang Cancer Hospital
Oesophageal Squamous Cell Carcinoma
NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma
The investigators will conduct a prospective, single-arm study to evaluate the safety and feasibility of neoadjuvant therapy with anti-PD-L1 antibody (SHR-1316, Hengrui Medicine) in patients with resectable esophageal squamous…
- Trial name
- NATION1907II (NCT04215471)
- Testing
- PD-L1 Antibody SHR-1316
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophagus Cancer
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group
- Trial name
- NCT07046221
- Testing
- Tislelizumab, Albumin-Bound Paclitaxel, cis-platinum
- Volunteers
- 60 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
This study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1…
- Trial name
- NCT07524452
- Testing
- Neoadjuvant and Adjuvant Becotatug Vedotin, Neoadjuvant and Adjuvant Immunotherapy, Surgery
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Ming-Yuan Chen
Esophageal Cancer
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00258297
- Testing
- gefitinib, conventional surgery, enzyme inhibitor therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Esophageal Squamous Cell Carcinoma (ESCC)
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
This study includes patients with resectable esophageal squamous cell carcinoma who will undergo local radiotherapy (PTV: 1.5Gy Bid, for 5 days), followed by neoadjuvant treatment with Serplulimab combined with cisplatin and…
- Trial name
- NCT07403435
- Testing
- Serplulimab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for squamous cell carcinoma of the head and…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05726370
- Testing
- Pembrolizumab, CISPLATIN, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Squamous Cell Carcinoma
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma
The goal of this observational study is to learn about the Effects of neoadjuvant therapy with carboplatin, paclitaxel combined with anti-PD-1 drugs on cognitive function in patients with resectable head and neck squamous cell…
- Trial name
- NCT06576180
- Testing
- Carboplatin（ neoadjuvant）, Paclitaxel （neoadjuvant）, Anti-PD-1 Drugs
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell…
- Trial name
- NCT07465276
- Testing
- Ficerafusp alfa, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
The investigators hypothesize that Tadalafil treatment, by lowering Myeloid Derived Suppressor Cells (MDSCs) and regulatory T cells (Tregs), can prime an antitumor immune response and promote a permissive environment that should…
- Trial name
- NCT02544880
- Testing
- Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Donald T. Weed, MD, FACS
Esophageal Squamous Cell Carcinoma
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
This is a study to evaluate the efficacy and safety of preoperative treatment with durvalumab combined with neoajuvant therapy (carboplatin, paclitaxel with/without radiation) in locally advanced resectable oesophageal squamous…
- Trial name
- NCT04568200
- Testing
- Durvalumab, Carboplatin, Paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This is a study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in resectable locally advanced esophageal squamous cell carcinoma patients
- Trial name
- NCT05302011
- Testing
- Pembrolizumab, Carboplatin or Cisplatin, Docetaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking Union Medical College Hospital